L-Dopa and amantadine hydrochloride were separately given to patients with diverse extra-pyramidal disorders including progressive supranuclear palsy; porto-systemic encephalopathy; oculogyric crises; drug-induced Parkinsonism; Huntington's chorea, hemiballismus; spasmodic torticollis, familial tremor; and athetosis. Akinesia and rigidity were improved in the first two conditions and simultaneously there was improvement in disordered eye movement. Amantadine provoked an exacerbation in spasmodic torticollis and familial tremor. No other condition was influenced. Both amantadine and L-dopa will facilitate eye movement mechanisms: it seems probable that both drugs act on dopamine-sensitive areas within the CNS. Neither drug will give significant benefit in the above disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2467156 | PMC |
| http://dx.doi.org/10.1136/pgmj.47.544.116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Clin Neuropharmacol
January 2025
MedStar Georgetown University Hospital, Washington, DC.
Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.
Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.
Unveiling the Therapeutic Potential of Small Molecule of SVAK-12: A Comprehensive In Silico, In Vitro, and In Vivo Studies on its Neuroprotective Effects and Molecular Interactions in Parkinson's Disease.
Curr Med Chem
October 2024
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopamine-producing cells, and current treatments are not definitive.
- The study explored the potential of SVAK-12, a small molecule capable of crossing the blood-brain barrier, to improve cell viability and reduce neurotoxicity in various experimental settings, including in vitro, in vivo, and through molecular simulations.
- Results showed that SVAK-12 increased levels of key neurotrophic factors and boosted dopamine expression, making it a promising candidate for treating neurological disorders despite limited impact on motor symptoms in live models.
Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.
PLoS One
October 2024
Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Background: Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice.
Methods: We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS.
Spectrum of delayed post-hypoxic leukoencephalopathy syndrome: A systematic review.
World J Clin Cases
October 2024
Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01655, United States.
Article Synopsis
- Delayed post hypoxic leukoencephalopathy syndrome (DPHLS) is a rare neurological condition that emerges weeks after hypoxia, causing cognitive and neurological deficits that are challenging to diagnose and treat.
- The study aims to gather and synthesize existing knowledge on DPHLS, focusing on its biological mechanisms, symptoms, diagnostic methods, and management while identifying areas needing more research.
- A review of 73 cases indicated that hypoxia often results from substance overdoses (like benzodiazepines and opioids), with common symptoms including cognitive decline and abnormal neuroimaging findings showing changes in the brain's white matter.
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.
Front Immunol
October 2024
Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, CA, United States.
Article Synopsis
- - A patient experienced movement and neurocognitive toxicity after receiving ciltacabtagene autoleucel, which did not improve with standard immunosuppression treatments.
- - The patient's symptoms responded positively to a combination of dopaminergic therapies, including carbidopa/levodopa, ropinirole, and amantadine.
- - This case marks the first documented instance of effective symptomatic treatment for a well-known neurotoxic syndrome associated with this therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!